FDA's RSABE on NTIDs in R [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2018-03-01 23:39 (1335 d 05:20 ago) – Posting: # 18492
Views: 12,062

Dear CECIF,

» Now, If I understand correctly this is bioequivalent because:
»
» 1. 95% CI of RSABE criterion= -0.009828289 <0

Correct.

» 2. Conventional ABE test: 0.9 < 0.9429483, 1.11>1.029172 (or is it also with conventional limits 0.8 and 1.25?).

As Detlew already pointed out: 80–125%. See the guidance:

Use the unscaled average bioequivalence procedure to determine BE for individual PK parameter(s). […] should pass […] also regular unscaled bioequivalence limits of 80.00-125.00%.


» 3. Upper 90% CI of the ratio swT/swR: 0.6842668<=2.5

Correct.

» In addition to this, do I still have to demonstrate conventional bioequivalence for:
» » 1. Period 1 vs period 2 (regular bioequivalence study)
» » 2. Period 3 vs period 4 (replicated study)
» » 3. Pooled analysis (Average periods 1 and 3 vs average period 2 and 4)
» ?
» as they do here? https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40301_Warfarin%20Sodium_Approv.pdf

Again, as Detlew wrote: No.
BTW, I don’t see such a (strange) requirement in the ANDA of 1999 (!) you linked.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,758 posts in 4,550 threads, 1,544 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Wednesday 05:59 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5